Developer docs
API playgroundTry for free, no card

Search company profiles

Chromatan

Full company profile

uuid0009emp

Namestring
Chromatan
Legal namestring
ChromaTan Inc.
Websiteurl
chromatan.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

ChromaTan Inc. is a privately held Pennsylvania-based biotechnology process equipment company founded in 2009 that develops continuous countercurrent tangential chromatography (CCTC) systems for biopharmaceutical purification. Its flagship product, the Kascade BioRMB system, is a patented column-free chromatography platform based on Biologic Real Moving Bed (BioRMB) true moving bed technology that uses hollow fiber membranes and multi-stage countercurrent extraction to deliver continuous, steady-state purification of biologics at low pressure, with stated advantages of 10X resin volume reduction, up to 70% OpEx savings, and 10–15X productivity improvements versus traditional packed bed chromatography. The platform is validated across sensitive modalities including monoclonal antibodies, AAV gene therapy vectors, mRNA therapeutics, lentivirus, and plasmid DNA, and integrates with a broader partner ecosystem spanning Purolite (custom resin), Proconex/Emerson DeltaV (automation), Securecell (process control software), PendoTECH (in-line sensors), and Shimadzu (analytics).

ChromaTan generates revenue through three streams: sale of Kascade BioRMB hardware systems (quote-based, multi-year contracts), R&D service contracts with major biopharmaceutical companies such as Roche, Takeda, and Merck, and licensing of BioRMB and CCTC patents. Its go-to-market is enterprise field sales targeting biopharmaceutical manufacturers and research institutions, supplemented by strategic R&D partnerships with pharmaceutical companies and academic institutions (MIT, Penn State) for technology validation and co-development. The company has been supported by substantial non-dilutive funding from NIH SBIR grants (over $7.7M cumulatively), FDA contracts ($2.5M awarded, $2.3M received), and NIIMBL awards ($1.3M cumulative), alongside equity financing totaling approximately $2.1M in Series A plus bridge rounds.

The company is headquartered at Spring House Innovation Park in Lower Gwynedd, Pennsylvania, with engineering/R&D origins in State College, PA and a prior Philadelphia Science Center location. As of 2024, ChromaTan reported 11–50 employees and shipped its first two commercial Kascade units to MIT and CSL Seqirus, marking its transition from development-stage to early commercial-stage operation with a focus on gene therapy manufacturing applications.

Short descriptiontext

ChromaTan is a private Pennsylvania-based biotech process equipment company that develops the Kascade BioRMB, a patented column-free continuous chromatography platform for purifying monoclonal antibodies, gene therapy vectors, mRNA, and other biologics, selling to biopharmaceutical manufacturers and research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmbler, United States
HQ citystring
Ambler
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous chromatography systems, biologics purification technology, monoclonal antibody purification, gene therapy manufacturing, biopharmaceutical processing equipment
Industry4 codes
PRIMARYHLAAAJAH
Continuous Bioprocessing Technologies (perfusion, continuous chromatography, integrated lines)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAA
Analytical Instruments & Chromatography Systems
SECONDARYHLAAAJAC
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Bioprocessing Chromatography Equipment
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Chromatography Hardware Sales
TypeHardware Sales
Description

Sale of Kascade BioRMB chromatography systems for advanced process development, preclinical and GMP manufacturing. Systems include flow rates of 2-25 mls/min and resin utilization of 7.5-50 mls.

chromatan.com
2R&D Service Contracts
TypeProfessional Services
Description

The company has received multiple R&D contracts from major pharmaceutical companies including Roche ($100,000), Takeda (long-term investigation), and Merck (long-term multi-phase contracts) for evaluating and developing the CCTC platform.

chromatan.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary BioRMB technology and CCTC patents for biopharmaceutical manufacturing applications.

chromatan.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Kascade BioRMB System for process development, preclinical and GMP manufacturing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing; systems sold with flow rates of 2-25 mls/min and resin utilization of 7.5-50 mls

chromatan.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ChromaTan develops and sells the Kascade BioRMB System, a column-free continuous chromatography platform based on proprietary Biologic Real Moving Bed (BioRMB) technology. The system performs true steady-state, low-pressure purification of biologics including monoclonal antibodies, gene therapy vectors (AAV), mRNA, and DNA, using disposable closed flowpaths with 10X resin volume reduction and up to 70% OpEx savings. The company also generates revenue through R&D service contracts with major pharmaceutical companies and licensing of its patented CCTC/BioRMB technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 10X resin volume reduction compared to traditional chromatography
+6 more records
Product overview1 text field

Chromatan offers the Kascade BioRMB System as its flagship product—a column-free chromatography platform based on Biologic Real Moving Bed (BioRMB) technology. This true moving bed technology provides continuous, steady-state purification of biologics with significantly reduced resin consumption and operational costs. The company also maintains earlier generation products (CCTC PiPe and CCTC Max) based on continuous countercurrent tangential chromatography technology. BioRMB represents the evolution and advancement of the original CCTC platform, with improved specifications and design optimizations extending through 2034.

Product and service3 records
1Kascade BioRMB System
CategoryBioprocessing chromatography hardware platform
Description

Column-free chromatography platform using true moving bed technology for continuous purification of biologics, featuring steady-state low-pressure operation, 10X resin volume reduction, up to 70% OpEx savings, disposable closed flowpath, and rapid resin cycling of 3-5 cycles per hour. Sold to biopharmaceutical manufacturers for process development, preclinical, and GMP manufacturing applications.

2CCTC PiPe
CategoryBioprocessing chromatography hardware platform
Description

Earlier generation continuous countercurrent tangential chromatography system from ChromaTan, predecessor to the Kascade BioRMB platform.

3CCTC Max
CategoryBioprocessing chromatography hardware platform
Description

Earlier generation continuous countercurrent tangential chromatography system from ChromaTan, predecessor to the Kascade BioRMB platform.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Shimadzu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

Joint R&D development on Process Analytical Solutions utilizing BioRMB for gene therapy manufacturing announced March 2025.

chromatan.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Received $700,000 NIIMBL award for joint development of next-generation solutions for gene therapy manufacturing, specifically for scalable and cost-effective AAV production processes.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-10-01
Description

Strategic partnership with Proconex (Emerson Impact Partner Network) for Emerson DeltaV process automation solutions. Proconex invested both cash and in-kind in ChromaTan's Series A and is jointly implementing complete automation solution for CCTC platform based on DeltaV.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

Major R&D contract with Takeda for long-term investigation of CCTC for Blood Plasma Purification. Part of $750,000 MLSC project with MIT for evaluation of platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Long-term multi-phase R&D contract with Merck to generate data with ChromaTan's technology. Merck has conveyed positive evaluation and case for further development and possible implementation.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-11-01
Description

$100,000 R&D contract to demonstrate CCTC platform capabilities as applied to commercial antibody-based therapy in Roche's pipeline.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-10-01
Description

Co-published white paper on utilization of in-line sensors in continuous processing for Bioprocess International. PendoTECH provides sensor technology for CCTC platform monitoring.

8Applikon Biotechnology
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-09-01
Description

Co-published white paper on Integrated Continuous and Single-use Bioproduction Platform (ICS) exploring optimization of Perfusion and Cell separation device (Biosep). Joint work under NIH Phase I grant.

chromatan.com
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2018-06-01
Description

Partnership to introduce Securecell's Numera in-line sampling platform and Lucullus software solution to integrate into ChromaTan's continuous bioprocessing solutions for process control and in-line sample prep and analysis.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-03-01
Description

First award in NIIMBL history - $600,000 awarded to develop in-line NMR instrument for protein concentration and aggregation measurements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-06-01
Description

Strategic collaboration on chromatography resin development resulting in innovative new resin specifically designed for CCTC platform. Joint publication demonstrating 140 grams mAb/L resin/hr - highest ever recorded productivity. Purolite joined ChromaTan at BPI 2018 exhibitor booth.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2009-08-01
Description

Partnership established at Penn State University Fenske Laboratory for countercurrent chromatography development. Dr. Zydney serves as Chair of ChromaTan's Technical Advisory Board. Long-term collaboration on CCTC technology development and publications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cytiva (formerly GE Healthcare Life Sciences) is the global leader in bioprocess chromatography with ÄKTA and MabSelect product lines, plus a full biomanufacturing portfolio. Directly comparable to ChromaTan as a chromatography platform provider serving the same biopharma manufacturers.

TypeDirect peer
Description

Repligen specializes in bioprocessing solutions including chromatography columns, flow-through systems, and process analytics for biologics manufacturing. A direct peer to ChromaTan focused on chromatography innovation with comparable end customers in biopharma production.

TypeBroad incumbent
Description

Sartorius is a major bioprocess equipment and consumables provider offering chromatography systems, single-use solutions, and process intensification tools. Competes with ChromaTan for the same biopharmaceutical purification customers across mAb and emerging modality manufacturing.

TypeBroad incumbent
Description

Bio-Rad's life science segment supplies chromatography resins (e.g., Nuvia, UNOsphere), systems, and process development tools to biopharma manufacturers. Comparable to ChromaTan as a chromatography-focused provider serving similar biologics purification applications.

TypeDirect peer
Description

Tosoh Bioscience specializes in chromatography resins, columns, and process-scale purification systems for biopharmaceutical manufacturing. A direct peer to ChromaTan competing in the same chromatography market with comparable customer base in mAb and biologics production.

TypeBroad incumbent
Description

Pall, part of Danaher's bioprocess segment, supplies chromatography, filtration, and single-use systems to biopharma manufacturers. Comparable to ChromaTan across bioprocess equipment serving similar customers in mAb and gene therapy production.

TypeBroad incumbent
Description

Thermo Fisher's bioproduction and chromatography business (including POROS resins and related systems) competes directly with ChromaTan in serving mAb and gene therapy manufacturers with purification technologies and integrated bioprocess solutions.

TypeEmerging player
Description

Shimadzu is ChromaTan's March 2025 R&D partner for process analytical solutions in gene therapy manufacturing. Comparable as an analytical instrumentation provider serving the same bioprocess and biopharma analytical markets with adjacent chromatography and process monitoring technology.

TypeEmerging player
Description

Purolite is a chromatography resin manufacturer and ChromaTan's strategic collaboration partner (joint resin development yielding record 140g mAb/L/hr productivity). Comparable as a specialized chromatography player serving the same biopharma customers, though focused on resins rather than systems.

TypeBroad incumbent
Description

MilliporeSigma is Merck's life science arm offering a broad bioprocessing portfolio including chromatography resins, systems, and single-use solutions. Comparable as both a ChromaTan partner (multi-phase R&D contract) and the dominant competitor in chromatography consumables and equipment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chromatan

Bioprocessing Chromatography Equipmentchromatan.com

ChromaTan is a private Pennsylvania-based biotech process equipment company that develops the Kascade BioRMB, a patented column-free continuous chromatography platform for purifying monoclonal antibodies, gene therapy vectors, mRNA, and other biologics, selling to biopharmaceutical manufacturers and research institutions.

What Chromatan does

ChromaTan Inc. is a privately held Pennsylvania-based biotechnology process equipment company founded in 2009 that develops continuous countercurrent tangential chromatography (CCTC) systems for biopharmaceutical purification. Its flagship product, the Kascade BioRMB system, is a patented column-free chromatography platform based on Biologic Real Moving Bed (BioRMB) true moving bed technology that uses hollow fiber membranes and multi-stage countercurrent extraction to deliver continuous, steady-state purification of biologics at low pressure, with stated advantages of 10X resin volume reduction, up to 70% OpEx savings, and 10–15X productivity improvements versus traditional packed bed chromatography. The platform is validated across sensitive modalities including monoclonal antibodies, AAV gene therapy vectors, mRNA therapeutics, lentivirus, and plasmid DNA, and integrates with a broader partner ecosystem spanning Purolite (custom resin), Proconex/Emerson DeltaV (automation), Securecell (process control software), PendoTECH (in-line sensors), and Shimadzu (analytics).

ChromaTan generates revenue through three streams: sale of Kascade BioRMB hardware systems (quote-based, multi-year contracts), R&D service contracts with major biopharmaceutical companies such as Roche, Takeda, and Merck, and licensing of BioRMB and CCTC patents. Its go-to-market is enterprise field sales targeting biopharmaceutical manufacturers and research institutions, supplemented by strategic R&D partnerships with pharmaceutical companies and academic institutions (MIT, Penn State) for technology validation and co-development. The company has been supported by substantial non-dilutive funding from NIH SBIR grants (over $7.7M cumulatively), FDA contracts ($2.5M awarded, $2.3M received), and NIIMBL awards ($1.3M cumulative), alongside equity financing totaling approximately $2.1M in Series A plus bridge rounds.

The company is headquartered at Spring House Innovation Park in Lower Gwynedd, Pennsylvania, with engineering/R&D origins in State College, PA and a prior Philadelphia Science Center location. As of 2024, ChromaTan reported 11–50 employees and shipped its first two commercial Kascade units to MIT and CSL Seqirus, marking its transition from development-stage to early commercial-stage operation with a focus on gene therapy manufacturing applications.

Chromatan firmographics

Firmographics
Name
Chromatan
Legal name
ChromaTan Inc.
Website
https://chromatan.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
ChromaTan is a private Pennsylvania-based biotech process equipment company that develops the Kascade BioRMB, a patented column-free continuous chromatography platform for purifying monoclonal antibodies, gene therapy vectors, mRNA, and other biologics, selling to biopharmaceutical manufacturers and research institutions.
Ownership category
akta.pro rank

Chromatan industry classification

Industry
Product category
Bioprocessing Chromatography Equipment
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Equipment and Supplies Manufacturing (3391)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAJAH
Continuous Bioprocessing Technologies (perfusion, continuous chromatography, integrated lines)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAA
Analytical Instruments & Chromatography Systems
SECONDARYHLAAAJAC
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Continuous chromatography systems
  • Biologics purification technology
  • Monoclonal antibody purification
  • Gene therapy manufacturing
  • Biopharmaceutical processing equipment

Where Chromatan is headquartered

Location

Headquarters

HQ city
Ambler
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Chromatan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Chromatography Hardware Sales: Sale of Kascade BioRMB chromatography systems for advanced process development, preclinical and GMP manufacturing. Systems include flow rates of 2-25 mls/min and resin utilization of 7.5-50 mls.
  2. R&D Service Contracts: The company has received multiple R&D contracts from major pharmaceutical companies including Roche ($100,000), Takeda (long-term investigation), and Merck (long-term multi-phase contracts) for evaluating and developing the CCTC platform.
  3. Technology Licensing: Licensing of proprietary BioRMB technology and CCTC patents for biopharmaceutical manufacturing applications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractKascade BioRMB System for process development, preclinical and GMP manufacturing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Chromatan product offering

Product offering

Core offering

ChromaTan develops and sells the Kascade BioRMB System, a column-free continuous chromatography platform based on proprietary Biologic Real Moving Bed (BioRMB) technology. The system performs true steady-state, low-pressure purification of biologics including monoclonal antibodies, gene therapy vectors (AAV), mRNA, and DNA, using disposable closed flowpaths with 10X resin volume reduction and up to 70% OpEx savings. The company also generates revenue through R&D service contracts with major pharmaceutical companies and licensing of its patented CCTC/BioRMB technology.

Product overview

Chromatan offers the Kascade BioRMB System as its flagship product—a column-free chromatography platform based on Biologic Real Moving Bed (BioRMB) technology. This true moving bed technology provides continuous, steady-state purification of biologics with significantly reduced resin consumption and operational costs. The company also maintains earlier generation products (CCTC PiPe and CCTC Max) based on continuous countercurrent tangential chromatography technology. BioRMB represents the evolution and advancement of the original CCTC platform, with improved specifications and design optimizations extending through 2034.

Differentiator

Problem solved

Functional benefit

Products and services

  • Kascade BioRMB System Column-free chromatography platform using true moving bed technology for continuous purification of biologics, featuring steady-state low-pressure operation, 10X resin volume reduction, up to 70% OpEx savings, disposable closed flowpath, and rapid resin cycling of 3-5 cycles per hour. Sold to biopharmaceutical manufacturers for process development, preclinical, and GMP manufacturing applications.
  • CCTC PiPe Earlier generation continuous countercurrent tangential chromatography system from ChromaTan, predecessor to the Kascade BioRMB platform.
  • CCTC Max Earlier generation continuous countercurrent tangential chromatography system from ChromaTan, predecessor to the Kascade BioRMB platform.

Quantifiable outcome

  • 10X resin volume reduction compared to traditional chromatography
  • +6 more outcomes

Companies that use Chromatan

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Chromatan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

Feature6 records

Chromatan partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and major.

  • ShimadzucoreStrategic or Co-development Partner · 1 March 2025Joint R&D development on Process Analytical Solutions utilizing BioRMB for gene therapy manufacturing announced March 2025.
  • Landmark BiocoreStrategic or Co-development Partner · 1 February 2025Received $700,000 NIIMBL award for joint development of next-generation solutions for gene therapy manufacturing, specifically for scalable and cost-effective AAV production processes.
  • ProconexcoreTechnology or Integration · 1 October 2020Strategic partnership with Proconex (Emerson Impact Partner Network) for Emerson DeltaV process automation solutions. Proconex invested both cash and in-kind in ChromaTan's Series A and is jointly implementing complete automation solution for CCTC platform based on DeltaV.
  • TakedacoreStrategic or Co-development Partner · 1 May 2019Major R&D contract with Takeda for long-term investigation of CCTC for Blood Plasma Purification. Part of $750,000 MLSC project with MIT for evaluation of platform.
  • MerckcoreStrategic or Co-development Partner · 1 January 2019Long-term multi-phase R&D contract with Merck to generate data with ChromaTan's technology. Merck has conveyed positive evaluation and case for further development and possible implementation.
  • RochemajorStrategic or Co-development Partner · 1 November 2018$100,000 R&D contract to demonstrate CCTC platform capabilities as applied to commercial antibody-based therapy in Roche's pipeline.
  • PendoTECHmajorStrategic or Co-development Partner · 1 October 2018Co-published white paper on utilization of in-line sensors in continuous processing for Bioprocess International. PendoTECH provides sensor technology for CCTC platform monitoring.
  • Applikon BiotechnologymajorStrategic or Co-development Partner · 1 September 2018Co-published white paper on Integrated Continuous and Single-use Bioproduction Platform (ICS) exploring optimization of Perfusion and Cell separation device (Biosep). Joint work under NIH Phase I grant.
  • SecurecellmajorTechnology or Integration · 1 June 2018Partnership to introduce Securecell's Numera in-line sampling platform and Lucullus software solution to integrate into ChromaTan's continuous bioprocessing solutions for process control and in-line sample prep and analysis.
  • University of MarylandmajorStrategic or Co-development Partner · 1 March 2018First award in NIIMBL history - $600,000 awarded to develop in-line NMR instrument for protein concentration and aggregation measurements.
  • Purolite Life SciencescoreStrategic or Co-development Partner · 1 June 2017Strategic collaboration on chromatography resin development resulting in innovative new resin specifically designed for CCTC platform. Joint publication demonstrating 140 grams mAb/L resin/hr - highest ever recorded productivity. Purolite joined ChromaTan at BPI 2018 exhibitor booth.
  • Penn State University / Dr. Andrew ZydneycoreStrategic or Co-development Partner · 1 August 2009Partnership established at Penn State University Fenske Laboratory for countercurrent chromatography development. Dr. Zydney serves as Chair of ChromaTan's Technical Advisory Board. Long-term collaboration on CCTC technology development and publications.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Chromatan competitors and assessment

Company assessment

Broad incumbents

  • Cytiva: Cytiva (formerly GE Healthcare Life Sciences) is the global leader in bioprocess chromatography with ÄKTA and MabSelect product lines, plus a full biomanufacturing portfolio. Directly comparable to ChromaTan as a chromatography platform provider serving the same biopharma manufacturers.
  • Sartorius: Sartorius is a major bioprocess equipment and consumables provider offering chromatography systems, single-use solutions, and process intensification tools. Competes with ChromaTan for the same biopharmaceutical purification customers across mAb and emerging modality manufacturing.
  • Bio-Rad Laboratories: Bio-Rad's life science segment supplies chromatography resins (e.g., Nuvia, UNOsphere), systems, and process development tools to biopharma manufacturers. Comparable to ChromaTan as a chromatography-focused provider serving similar biologics purification applications.
  • Pall Corporation (Danaher): Pall, part of Danaher's bioprocess segment, supplies chromatography, filtration, and single-use systems to biopharma manufacturers. Comparable to ChromaTan across bioprocess equipment serving similar customers in mAb and gene therapy production.
  • Thermo Fisher Scientific: Thermo Fisher's bioproduction and chromatography business (including POROS resins and related systems) competes directly with ChromaTan in serving mAb and gene therapy manufacturers with purification technologies and integrated bioprocess solutions.
  • Merck (MilliporeSigma): MilliporeSigma is Merck's life science arm offering a broad bioprocessing portfolio including chromatography resins, systems, and single-use solutions. Comparable as both a ChromaTan partner (multi-phase R&D contract) and the dominant competitor in chromatography consumables and equipment.

Direct peers

  • Repligen: Repligen specializes in bioprocessing solutions including chromatography columns, flow-through systems, and process analytics for biologics manufacturing. A direct peer to ChromaTan focused on chromatography innovation with comparable end customers in biopharma production.
  • Tosoh Bioscience: Tosoh Bioscience specializes in chromatography resins, columns, and process-scale purification systems for biopharmaceutical manufacturing. A direct peer to ChromaTan competing in the same chromatography market with comparable customer base in mAb and biologics production.

Emerging players

  • Shimadzu Scientific Instruments: Shimadzu is ChromaTan's March 2025 R&D partner for process analytical solutions in gene therapy manufacturing. Comparable as an analytical instrumentation provider serving the same bioprocess and biopharma analytical markets with adjacent chromatography and process monitoring technology.
  • Purolite Life Sciences: Purolite is a chromatography resin manufacturer and ChromaTan's strategic collaboration partner (joint resin development yielding record 140g mAb/L/hr productivity). Comparable as a specialized chromatography player serving the same biopharma customers, though focused on resins rather than systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Chromatan social profiles

Digital presence

Chromatan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chromatan leadership team

Management profile

Number of profiles

Profiles7 records

Chromatan funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chromatan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chromatan

What does Chromatan do?

ChromaTan develops and sells the Kascade BioRMB System, a column-free continuous chromatography platform based on proprietary Biologic Real Moving Bed (BioRMB) technology. The system performs true steady-state, low-pressure purification of biologics including monoclonal antibodies, gene therapy vectors (AAV), mRNA, and DNA, using disposable closed flowpaths with 10X resin volume reduction and up to 70% OpEx savings. The company also generates revenue through R&D service contracts with major pharmaceutical companies and licensing of its patented CCTC/BioRMB technology.

Is Chromatan a public or private company?

Chromatan is a private company. It is classified as venture growth investor backed and is currently operating.

When was Chromatan founded?

Chromatan was founded in 2009. It employs 11 to 50 people.

Where is Chromatan based?

Chromatan is headquartered in Ambler, United States, in the North America region.

How does Chromatan make money?

Three revenue lines are on record. Chromatography Hardware Sales are the primary driver. The others are R&D Service Contracts and technology Licensing.

Who are Chromatan's main competitors?

Broad incumbents on record are Cytiva, Sartorius, Bio-Rad Laboratories, Pall Corporation (Danaher), Thermo Fisher Scientific and Merck (MilliporeSigma). Direct peers are Repligen and Tosoh Bioscience. Emerging players are Shimadzu Scientific Instruments and Purolite Life Sciences.

Does Chromatan have an API?

No public API is recorded for Chromatan.

What industry is Chromatan in?

Chromatan's product category is Bioprocessing Chromatography Equipment. Its primary akta.pro industry code is HLAAAJAH, Continuous Bioprocessing Technologies (perfusion, continuous chromatography, integrated lines), with a secondary code of HLAGAIAA, Analytical Instruments & Chromatography Systems. Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechnicalAfter 15 years, ChromaTan’s drug-purification fix is nearing commercializationChromaTan, a Spring House, Pennsylvania-based biotech startup founded in 2013, has spent 15 years developing equipment that purifies biologic drugs using 10 to 20 times less resin than traditional chromatography, potentially cutting one of the most expensive steps in drug manufacturing. The company has raised approximately $23 million and currently has five customers using pilot-scale systems as it pursues a $10 million Series B round in a difficult private funding market. ChromaTan is now transitioning from development to commercialization, though convincing manufacturers to replace trusted equipment will require additional funding, testing, and proof the approach scales effectively.PR NewswireChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production ProceChromaTan and Landmark Bio received a NIIMBL grant to develop an intensified AAV production process. The collaboration will use ChromaTan's BioRMB technology and Landmark Bio's expertise to improve purification efficiency and process intensification. The project aims to reduce resin costs and lower the cost of goods for AAV-based gene therapies.FinSMEsChromaTan Receives a $2M Phase IIB NIH GrantChromaTan received a $2M NIH IIB grant from the National Institute of General Medical Sciences. The funds will develop its BioRMB single-use, column-free chromatography platform for AAV purification, targeting at least two serotypes and scaling to cGMP production.Business & FinancialZoic Capital Participates In Seed Round Investment In Chromatan TechnologiesZoic Capital participated in a seed round for ChromaTan, a biotech developing CCTC purification systems that halve biologics purification costs and boost gene therapy yields. The company has early contracts with three top-20 pharma firms and a research contract with MIT.Business Wire BlogChromaTan™ Appoints Dr. Rajiv Datar as New CEOChromaTan appointed Dr. Rajiv Datar as President & CEO, succeeding Oleg Shinkazh, who remains CTO. Datar brings over 25 years of C-level experience in bioprocessing and drug development. The company aims to advance its continuous chromatography platform.TechnicalBen Franklin Tech Partners just pumped more than $1M into these local companiesBen Franklin Technology Partners invested over $1 million into six local tech and science companies, including CromaTan, Exyn Technologies, and four others. The funding was spread across the companies, with CromaTan receiving $250,000 and Exyn $200,000. The group reported 46 companies received $7.2 million in fiscal 2019.